-47.4%
NKE vs MRNA
+511.3%
-558.7%
-47.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.0% | -2.2% | +1.3% | -0.9% |
| 7D | -2.0% | +5.5% | -7.5% | -2.1% |
| 30D | -8.6% | +158.7% | -167.3% | -12.9% |
| 3M | -11.0% | +182.1% | -193.2% | -16.9% |
| 6M | -33.2% | +151.8% | -185.0% | -37.2% |
| YTD | -38.1% | +393.6% | -431.7% | -44.6% |
| 1Y | -47.4% | +499.5% | -546.8% | -55.7% |
| All | -47.4% | +511.3% | -558.7% | -55.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling